

HLA prevalence in Iraqi patients with ischemic heart disease

Basil N. AL-Dileamy*

Eman Sh. AL-Obeidy**

MRCP, MD, FACC

BSc, PhD

Summary:

Background: The etiology of ischemic heart disease (IHD) is believed to have an immunological component. Association with human leukocyte antigens (HLAs) has been previously reported, particularly with DR6.

Patients and methods: 75 cardiac patients were admitted to the coronary care unit, Baghdad Teaching Hospital over the period October 2008-May 2009 with the clinical diagnosis of acute coronary syndrome and STEMI myocardial infarction their ages range was (25-82) years the number of male was (55) (73.3%) and female was (20) (26.7%). All cases have routine ECG, cardiac marker's measurements, routine haematological, Biochemical test and 2mls of blood reserved for HLA study.

Results: It was found that HLA-DR1 (8%) (P 0.001) has significant risk factor in the development of ischemic heart disease while HLA B (62%) (P 0.0009) has a protection factor in ischemic heart disease.

Conclusions: Our result suggests that strong relation between the incidence of acute ischemic episode (acute coronary syndrome and STEMS myocardial infarction and HLA-DR1) which mean that there may be predisposing genetic factor for the development ischemic heart disease.

Key words: Ischemic Heart Disease, Human Leukocyte Antigens.

*Fac Med Baghdad
2010; Vol. 52, No. 2
Received May 2009
Accepted Dec. 2009*

Introduction:

Ischemic heart disease is a complex of clinical symptoms of various pathogenesis caused by insufficient oxygen and nutritional compounds supply in relation to the actual requirement of the myocardium. However the most important factors for increased incidence of ischemic heart disease is the presence of predisposing factors like age, sex, atherogenic diet smoking, lack of physical activity, obesity, excessive consumption of Alcohol, abnormal lipid profile, high Blood pressure, Hyperglycemia, elevated concentration of homocysteine and fibrinogen. Another important role in the development of ischemic heart disease is the genetic factor.(1,2) Since they affect the development ischemic heart disease via the process of polymorphism in which there will be genetically transmitted mutation of DNA. Another aspect of association of ischemic heart disease is HLA system. The major histocompatibility complex (MHC) is a complex locus, composed of a large cluster of genes located on the short arm of chromosome 6 (3). MHC products are expressed on surface of a variety of cell in human, these are known as HLA-Ags (3, 4). The human MHC, comprises three major classes (I, II, III) of genes involved in the immunr response.

Class I: molecules are a glycoprotein's and dividend two families, HLA Ib encoded by genes at the A, B and C loci in the HLA on chromosome 6(5, 6, 7, 8). C locus in immunologically important.

Class II: molecules are the MHC class II genes encode a glycoprotein.

These molecules are consist of two non covalently linked polypeptide chains, α chain and β chain encoded by DR-DQ and DP regions (6, 9) (DP immunologically most important).

The MHC region between class I and class II is called class III region contain several different genes coding for complements C2, C4, BF, two cytokines (TNF α and β), two HSP (hsp 70-1& 70-2) "one of family produced by cells in response to heart and injuries" and 21 hydroxylase "an enzyme important in steroid metabolism"(10, 11).

Patients and Methods:

75 cardiac patients with history of acute coronary syndrome and acute myocardial infarction (STEMS) admitted to the coronary care unit, Baghdad teaching hospital over the period October 2008-May 2009. Their age range was age 55 ± 30 (25-82) the Number of male were 55 and female were 20 and (value) and the male to female into was 2.7:1. 50 healthy central (age, sex, matched) were enrolled in this study. Both patients and control went thought the same uniform questionnaire, which includes (clinical history, clinical examination, routine blood test, cardiac markers, electrocardiography, and echocardiography). These patients did not have any other chronic disorders like malignancy, reneal falure, thyroid disorder, diabetes mellitus, and connective tissue disease.

Both groups were typed for HLA-class I (A&B) and class II (DR-DQ) antigens. The basic material for typing with Histo-type DNA-ssp sequence specific primers kit is purified kit. The test procedure was done by using the sequence specific primers (ssp). This method is based in the fact that primer extension and hence successful polymerase chain

* Department of Medicine, College of Medicine, University of Baghdad.

**Department of immunology, center teaching laboratory, Baghdad Medical city.

reaction (PCR) relies on the exact match at the 3-end of both primers

Results:

The frequency of distribution of various class I HLA-Ags for both patients & control groups were shown in tables (1 and 2). The HLA-A locus, comparison between IHD patients and healthy control groups showed no significant association between several antigens regarding their frequencies distribution. Studying HLA-B locus, it has been found the B7 was showing increased frequencies in healthy control group in comparison to patients (15.0% Vs 5.0%) then patients and therefore this may represent a protective factor against the disease with p value 0.009. Studying the DR- alleles, It has been found that DR-1 showing high frequency in patients group in comparison to control group (p value <0.001) as shown in table 3.

Table-1: Antigens frequency of the HLA-A (% , P) of the IHD patients and healthy control.

HLA antigen	Healthy control		Ischemic heart cases		P
	No=50		No=75		
HLA-A	N	%	N	%	
1	15	30.0	25	25.0	NS
2	33	58.0	35	52.0	NS
3	6	12.0	11	11.0	NS
9	3	6.0	5	5.0	NS
10	1	2.0	3	3.0	NS
11	5	10.0	7	7.0	NS
23	2	4.0	5	5.0	NS
24	10	20.0	18	18.0	NS
25	1	2.0	3	3.0	NS
26	3	6.0	4	4.0	NS
28	4	8.0	2	2.0	NS
29	3	6.0	2	2.0	NS
30	3	6	4	4.0	NS
31	2	4.0	4	4.0	NS
32	2	4.0	2	2.0	NS
33	2	4.0	3	3.0	NS
34	1	2.0	2	2.0	NS
36	1	2.0	4	4.0	NS

Table-3 below revealed the importance of DR-alleles through their frequencies in IHD patients in comparison with healthy controls. As shown, DR1 found in high frequencies in patients compared to healthy control groups with (P value <0.0001).

A survey of the distribution of HLA-DQ frequency yielded no evident association between DQ Ag and IHD patients, (table-4).

So from all what had been mentioned previously it appeared that DR-1 formed a big significant difference between patients and the normal persons since its P value was <0.0001, while the strongest protective antigen was HLA-B7 with P value (0.009).

Table-2: Antigens frequency of the HLA-B (% , P) of the IHD patients and healthy control.

HLA antigen	Health control		IHD cases		P
	No=50		No=75		
HLA-B	N	%	N	%	
5	3	6.0	4	4.0	NS
7	35	62.0%	3	3.0	0.009
8	7	14.0	9	9.0	NS
12	0	0.0	3	3.0	NS
13	0	0	0	0.0	NS
14	4	8.0	9	9.0	NS
15	1	2.0	3	3.0	NS
17	2	4	1	1.0	NS
18	5	10.0	5	5.0	NS
21	1	2.0	8	8.0	NS
22	0	0	0	0.0	NS
27	3	6.0	6	6.0	NS
35	4	8.0	2	2.0	NS
37	3	6	3	3.0	NS
38	5	10.0	7	7.0	NS
39	12	22.0	18	18.0	NS
40	2	4.0	1	1.0	NS
41	3	6	3	3.0	NS
44	6	12.0	4	4.0	NS
45	1	2.0	0	0.0	NS
47	1	2.0	1	1.0	NS
49	1	2	0	0.0	NS
50	1	2	1	1.0	NS
51	7	14.0	8	8.0	NS
52	1	2	0	0.0	NS
53	3	6.0	2	2.0	NS
54	0	0.0	1	1.0	NS
55	1	2.0	6	6.0	NS
56	1	2.0	2	2.0	NS
57	1	2.0	1	1.0	NS
60	0	0.0	1	1.0	NS
62	1	2.0	3	3.0	NS
63	1	2.0	2	2.0	NS
70	1	2.0	1	1.0	NS
73	0	0.0	2	2.0	NS

Table-3: Antigens frequency of the HLA-DR (% , P) of the IHD patients and healthy control.

HLA antigen	Healthy control		IHD cases		P
	No=50		No=75		
HLA-DR	N	%	N	%	
1	4	8.0	62		0.001
2	6	12	11	11.0	NS
3	10	20	12	18.0	NS
4	20	32.0	24	24.0	NS
5	2	4.0	4	4.0	NS
6	1	2	0	0.0	NS
7	32	52.0	44	48.0	NS
8	3	6.0	2	2.0	NS
9	1	2.0	0	0.0	NS
10	5	10.0	8	8.0	NS
11	3	3.0	6	6.0	NS
13	1	2.0	1	1.0	NS
14	2	4.0	4	4.0	NS
15	3	6	4	0.7	NS
52	5	10.0	6	6.0	NS
53	3	6.0	4	4.0	NS

Table-4: Antigens frequency of the HLA-DQ (% , P) of the IHD patients and healthy control.

HLA antigen	Healthy control		IHD cases		P
	No=50		No=75		
HLA-DQ	N	%	N	%	
1	13	26	26	26.0	NS
2	13	26.0	26	26.0	NS
3	10	20.0	18	18.0	NS
4	8	16.0	13	13.0	NS

Discussion:

The role of genetic factors in the etiology of different types of heart diseases was documented many decades ago. As a result, the investigative efforts were focused on the genetic markers of susceptibility to this disease. Moreover, the high familial incidence of heart diseases suggests the possibility of a linkage or an association of disease with MHC (8, 12), however, this study is the first report on the association of HLA class I and II with IHD in Iraqi patients.

In the present work, there was a significant association of HLA-DR1 with IHD patients ($p=0.001$). This result is in agreement with what reported by some researchers regarding significant statistical association of IHD with DR locus in comparison with healthy control group (6, 13).

Different results regarding this association was reported, results differ in different population. For instance Limas reported the association of HLA-Ag with IHD and observed an increase frequency of HLA-DR6 in Americans patients (7), other study reported by Palikhe and colleagues revealed an increased frequency of HLA-A2 in Finland patients (13, 14). However, other scientist failed to confirm such association (15, 16). There is no clear reason why some studies should be different from those already published, other than possible difference (17, 18, 19) arising from geographically and ethnically different populations.

So generally an immunological basis for IHD remains likely, but this disease is probably a heterogeneous condition and it may be that a strong immunological component is not a feature of all groups (20).

References:

- 1- Pario I, Leone AM, crea F, et al. Inflammation genetics and ischemic heart disease in focus on the major histocompatibility complex (MHC) genes catholic university medical school, Department of cardiovascular medicine, Rome, Italy. *Cytokine* 2005 Mar7; 29(5):187-96.
- 2- Swanberg M, et al. MHC 2TA in associated into deferential MHX molecule expression and susceptibility to Rheumatoid arthritis, multiple sclerosis and myocardial infarction. *Nat. Genet.* 2005; 37(5):486-94.
- 3- Stominger JL &Wiley DC. " The class I and II proteins of the human MHC". *JAMA.* 1995; 274: 1074-76.
- **4- klein J, sato A. *The HLA system.* N. Engl. J. Med. 2007; 7: 702-709.
- 5- Johanson A, Hurllet C, Hartman R. HLA: MHC of human and transplantation immunology. In: *clinical diagnosis and management by laboratory methods.* 9th Ed. Saunders, Philadelphia. 1996; 2: PP.958-78.
- 6- Dasgupta A. *Modern immunology.* 5th Ed. Jaypee Brotheres, New Delhi. 2002; PP.101-11.
- 7- Terai M, et al. *Class II major histo-compatibility antigen expression on coronary arterial endothelium*

in a patient with Kawasaki disease. Human pathol. 1990; 21(2): 231-4.

8- Palikle A, Sinsolo J, Seppanen M, et al. *Human MHCregin harbors both susceptibility and protective haplotype for coronary artery disease. Division of cardiology, Helsinki university central hospital, Helsinki, Finland.[Pubmed] 2007.*

9- Stern LJ, Wiely DC. *Antigenic peptide binding by class I and II histocompatibility proteins. Struturs.* 2005; 2:245-51.

10- Carpenter CB. *The MHC. In: Harrisons, principles of internal medicine.* 14th Ed., McGraw-Hill, 2006; 306: 1777-83

11- Thompson G, Robinson WP, Kuhner MB. *Genetic heterogeneity modes of inheritance and risk estimates for a joint study Caucasians with IDDM. Am. J. Hum. Genet.* 1998; 43: 799-816.

12- Carforio ALP, Bonifacio E, Stewart JT, et al. *Novel organ specific circulating cardiac autoantibodies in dilated cardiomyopathy. J. Am. Coll. Cardiol.* 1990;15: 1527-34.

13- Zerbe TR, Kaufmann C, Colson Y, Duquesnoy R. *Associations of HLA-A, B, DR antigens with primary disease in cardiac allograft recipients. Am. J. cardiol.* 1988;61:1359-61.

14- Komajda M, Raffoux C, Sasse E, et al. *HLA A-B and DR antigens in dilated cardiomyopathy. Arch. Mal. Coeur.* 1987; 80: 1233-7.

15- Arbustini E, Gavazzi A, Pozzi R, et al. *The morphological spectrum of dilated cardiomyopathy and its relation to immune response genes. Am. J. Cardiol.* 1989; 64: 991-5.

16- carlquist JF, Menlove RL, Murray MB, O'Connell JB, Anderson JL. *HLA class I (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Circulation.* 1991; 83: 515-22.

17- Limas CJ, Limas C. *HLA-DRw6 antigen linkage in chronic congestive heart failure secondary to coronary artery disease (ischemic cardiomyopathy). Am. J. cardiol.* 1988; 62:861-8.

18- Darke C, Dyer P. *Clinical HLA typing by cytotoxicity. In: Dyer P, Middleton D, Histocompatibility sessing, practical approach. Oxford: IRL.1993:51-80.*

19- Easage D, Baxter-Lowe L-A, Gorki J, Middleton D, eds. *Molecular methods in: Dyer P, Middleton D, Histocompatibility sessing, practical approach. Oxford: IRL.1993: 108-42.*

20- RD Levy, SCD Grant, S Sheldon, PA Dray, NH Brooks. *Do specific HLA antigens pre-dispose to coronary heart disease or congestive cardiomyopathy. Eur. Heart j.* 1992; 13(Supp1): 110.